9 news items
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
ZNTL
29 May 24
. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
ZNTL
23 May 24
-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
ZNTL
14 May 24
small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that members of the management team will participate
HC Wainwright & Co. Maintains Buy on Zentalis Pharma, Lowers Price Target to $40
ZNTL
8 May 24
HC Wainwright & Co. analyst Andrew Fein maintains Zentalis Pharma (NASDAQ:ZNTL) with a Buy and lowers the price target from $46 to $40.
Stifel Maintains Buy on Zentalis Pharma, Lowers Price Target to $32
ZNTL
8 May 24
Stifel analyst Bradley Canino maintains Zentalis Pharma (NASDAQ:ZNTL) with a Buy and lowers the price target from $36 to $32.
t8xiuxdwnvqmagrkzaytnq4d364ww1tbc2sg5h
ZNTL
1 May 24
. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting
p6apa1j5hm 9k655t7uchljjgqrbqj9b6a2sl
ZNTL
2 Apr 24
biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways
evx p4cghd2p8jrmbxfm83tnj0zd68hyzu7hbvog1cz6x0olz8ezdo0o
ZNTL
2 Apr 24
. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting
1goqghbmmfr33cs9vfy cy7pkjcx3sakrz8p3lvuqkmyudxcqfqgb
ZNTL
1 Apr 24
. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental
- Prev
- 1
- Next